Mitochondrial calcium ions promote a number of events that sustain ATP levels in the cell. Cardenas et al. (2010) now demonstrate that the inositol 1,4,5-triphosphate receptor at the endoplasmic reticulum constitutively provides calcium for mitochondria. In the absence of this calcium transfer, cells use autophagy to sustain survival.
reductase activity for TECR (GPSN2), confirming an earlier study, which had identified fatty acids as the substrates of this steroid 5α-reductase family member ( Figure 1B ) (Moon and Horton, 2003) .
The work of Cantagrel and coworkers is creatively exhaustive and nails down every aspect of a difficult research problem from yeast cultures to the clinic. Where could they possibly go from here? For one, their studies in mice with mutations in Srd5a3 suggest a regulatory crosstalk between the mevalonate pathway and N-linked protein glycosylation, and it will be interesting to determine the mechanism underlying this interplay. In addition, the substrate and physiological function of SRD5A2L are still unknown. Will this steroid 5α-reductase function in glycosylation or hormone production, or will it play a completely distinct role from that of its namesake?
Bone remodeling is a highly conserved and regulated process that controls calcium homeostasis within a very tight range and maintains the structural integrity of the skeleton. In this issue of Cell, tandem articles from independent laboratories (Fulzele et al., 2010; Ferron et al., 2010) provide fresh support for the hypothesis that the insulin regulatory system mediates communication between metabolic control and bone remodeling. Fulzele et al. (2010) provide compelling in vivo evidence, using conditional deletion of the insulin receptor in osteoblasts, that insulin signaling promotes bone formation by suppressing an inhibitor of osteoblast development, Twist2, and enhances expression of osteocalcin, a mediator of insulin sensitivity and secretion. Ferron et al. (2010) show that insulin signaling in osteoblasts mediates glucose homeostasis by stimulating the production of an inactive form of osteocalcin and by promoting osteoclastmediated bone resorption, which then releases the active form of osteocalcin. In this putative feed-forward loop, the complete bone remodeling process is involved, thereby linking skeletal homeostasis to energy regulation. Given that the findings from these papers may have profound implications for understanding and ultimately treating several metabolic conditions, a closer examination of these two reports is necessary to clarify where and how this regulatory loop is situated in the hierarchy of control mechanisms that define insulin signaling and bone turnover.
It has only been a decade since Ducy et al. (2000) demonstrated that leptin (an adipokine that regulates appetite, energy expenditure, and insulin secretion) influences bone remodeling through hypothalamic modulation of the sympathetic nervous system. Prior to that, skeletal remodeling was considered within its essential context of calcium conservation, a homeostatic process regulated by calciotropic hormones (such as parathyroid hormone and vitamin D), gonadal steroids (such as estrogen), and local growth factors (such as insulin-like growth factor I and transforming growth factor β). Subsequent work has provided stronger support for the tenet that leptin is a major, albeit indirect, mediator of skeletal turnover through neuronal circuits in the central nervous system (Lee et al., 2007; Yoshizawa et al., 2009 ). In addition the osteoblast-specific protein osteocalcin is reported to promote insulin secretion Fer- Advancing the hypothesis that bone remodeling is intimately linked to metabolic homeostasis, Fulzele et al. (2010) and Ferron et al. (2010) present evidence that insulin signaling promotes the activation of bone-forming osteoblasts and enhances production of osteocalcin, a secreted mediator of insulin sensitivity, through modulation of bone resorption.
Cell 142, July 23, 2010 ©2010 Elsevier Inc. 199 ron et al., 2008). Interestingly, osteocalcin undergoes gamma carboxylation in a vitamin K-dependent process prior to its secretion, although a relatively small fraction of osteocalcin is undercarboxylated and is released into the circulation. It is the latter form that is postulated to be active on adipocytes and insulin-producing pancreatic beta cells (Figure 1) (Lee et al., 2007) .
Several lines of evidence from the two new papers strengthen the proposal that osteocalcin is indeed the skeletal mediator of energy balance. For example, mice lacking osteocalcin have a metabolic phenotype nearly identical to that of mice with conditional deletion of the insulin receptor in osteoblasts. In addition, Fuzele et al. improve insulin sensitivity in mice lacking expression of the insulin receptor in osteoblasts with a 2 week infusion of undercarboxylated osteocalcin. Despite this treatment, the mice remain glucose intolerant, most likely as a result of a decrease in beta cell mass from chronic insulin resistance. Determining whether chronic infusions of undercarboxylated osteocalcin could fully rescue both the metabolic and obesity phenotypes of these mice will be critical for placing this protein in the regulatory hierarchy that controls insulin secretion and will provide an indicator of its future therapeutic utility.
The work by Ferron et al. reinforces the findings of Fuzele et al. and addresses some, but not all, of the questions raised since the Karsenty group first introduced the concept that the skeleton could regulate energy metabolism (Lee et al., 2007; . In prior work, osteocalcin has been shown to be regulated by the Esp gene, which encodes osteotesticular protein tyrosine phosphatase (OST-PTP). However, it has been unknown how OST-PTP suppresses levels of undercarboxylated osteocalcin. Using substrate trapping, Ferron et al. now identify a direct interaction between the insulin receptor and OST-PTP resulting in dephosphorylation and subsequent inactivation of the insulin receptor. In mice lacking OST-PTP, insulin sensitivity and secretion is markedly enhanced as a result of constitutive activation of the receptor. Osteoblast-specific deletion of one allele of the insulin receptor ameliorates the high levels of active undercarboxylated osteocalcin and normalizes the insulin tolerance of OST-PTP deficient mice.
A second issue has been the absence of a clearly defined link between bone turnover by insulin receptor activation and undercarboxylated osteocalcin. Intriguingly, in the conditional insulin receptor null mice, bone resorption is markedly reduced, whereas bone resorption is high in mice lacking OST-PTP. A prior report by Ferron and colleagues (Ferron et al., 2008) indicates that these changes are due to altered expression of osteoblast-derived osteoprotegerin (OPG), a secreted inhibitor of osteoclast maturation and activity. Although osteoclasts do not make osteocalcin, it has long been recognized that matrixderived osteocalcin can enter the circulation in substantial amounts during bone resorption. The new data from Ferron et al. clearly show that the acidic environment of the resorption pit is sufficient to decarboxylate, and therefore activate, osteocalcin. In support of this notion, when RANKL (receptor activator for nuclear factor κB ligand), the most powerful endogenous stimulators of resorption by osteoclasts, is administered to wild-type mice, undercarboxylated osteocalcin increases 3-fold. In contrast, mice with nonfunctional osteoclasts have reduced levels of undercarboxylated osteocalcin and exhibit a nearly identical metabolic phenotype to mice lacking osteocalcin. Moreover, reduction of osteoclast resorption with bisphosphonates rescues the enhanced insulin secretion and glucose tolerance observed in OST-PTP-deficient mice.
A third concern raised from earlier data relates to the absence of a human homolog for the Esp gene. Ferron again use substrate trapping with PTP1B, a tyrosine phosphatase in humans that dephosphorylates the insulin receptor, and show that decreasing expression of PTP1B with a small interfering RNA suppresses osteoprotegerin expression in vitro. Finally the authors present data from osteopetrotic patients (that is, individuals with impaired bone resorption) showing reduced serum undercarboxylated osteocalcin levels compared to controls, as well as impaired insulin secretion after a meal.
Despite these remarkable data, questions remain. First and foremost, there is still no known osteocalcin receptor. Hence, the mechanism of how underfigure 1. energy Regulation and Bone Turnover by the Insulin/ Osteocalcin Axis A putative feed-forward regulatory loop ties bone turnover to energy regulation as proposed by Ferron et al. (2010) and Fulzele et al. (2010) . Insulin activates skeletal remodeling (that is, increases bone formation by osteoblasts and resorption by osteoclasts), which in turn releases uncarboxylated osteocalcin from the skeletal matrix into the circulation. This enhances insulin secretion and increases the insulin sensitivity of adipocytes. A tyrosine phosphatase OST-PTP, which is encoded by the Esp gene, binds the insulin receptor (IR) and suppresses its activation through dephosphorylation. The transcription factor Twist2 is a critical downstream suppressor of osteoblast differentiation. Osteoprotegerin (OPG) is an osteoblast-specific inhibitor of RANKL, acting as a decoy receptor to block bone resorption. Hydroxyapatite is the mineral component of bone.
carboxylated osteocalcin increases pancreatic insulin production and secretion is not clear. Second, if bone resorption is so critical to the posttranslational modification of osteocalcin and therefore insulin secretion, are individuals on antiresorptive therapy for osteoporosis more likely to be insulin resistant and glucose intolerant? In a small observational study, Kaji et al. (2009) report that fasting glucose levels are higher in women treated for 2 years with alendronate, the most commonly used treatment for osteoporosis. However, fat mass does not differ in these patients, and the statistical relationship between bone density and fasting glucose disappears when corrected for changes in lean mass. In addition, previous human investigations clearly demonstrate that an oral glucose load that increases insulin secretion suppresses markers of bone resorption by 50% (Clowes et al., 2003) . Most importantly, and yet much more difficult to address, is whether the relationship between bone and energy metabolism provides an evolutionary advantage and, if so, where skeletal control fits into the complex hierarchy of acute and chronic regulation of insulin secretion during physiologic states. Notwithstanding these unanswered questions, these two studies provide a strong framework for understanding the emerging role of the skeleton in metabolic homeostasis.
Life is all about capturing energy and putting it to use seeking more energy, avoiding being someone else's energy, building and repairing parts, and making more life. In eukaryotic cells, the mitochondria are the processing plants where the major forms of energy currency, such as ATP, are generated by catabolism of nutrients and consumption of oxygen. Much of mitochondrial research of the last 50 years has focused on how this flow and conversion of energy is controlled. But it is only in the last few years that we have realized that this process is an important node in the complex signal transduction machinery that extends throughout the cell and connects it to the external environment. In a sense, we are seeking the links between information and energy in the cell. Now, a paper in this issue provides one such link: Cardenas et al. (2010) report that calcium constitutively released from the endoplasmic reticulum (ER) by the inositol 1,4,5-triphosphate receptor (IP 3 R) is taken up by mitochondria where it is required for efficient oxygen consumption and ATP production.
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